UpStream Bio Inc. UPB 深 沪
等待开盘 09-25 09:30:00 美东时间
16.75
+0.470
+2.89%
华盛通- 最 高16.78
- 今 开16.25
- 成交量 29.47万股
- 最 低 16.195
- 昨 收 16.28
- 总市值 9.01亿
- 52周最高 29.4599
- 市盈率 静 --
- 换手率 0.55%
- 52周最低 5.14
- 委 比 -25.04%
- 总股本 5379.37万
- 历史最高 29.4599
- 量 比 0.38
- 振 幅 3.59%
- 历史最低 5.14
- 每 手 1
- 风险率 5.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
Upstream Bio, Inc. (Nasdaq: UPB), a company developing treatments for inflammatory diseases with a focus on severe respiratory disorders, announced that CEO Rand Sutherland will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025, at 10:30 a.m. ET. The event will be webcast live and available for replay on the Company's website. Upstream Bio is advancing verekitug, a monoclonal antibod...
09-09 11:00
美股牛股 | 医药股彻底疯狂！美国联合医疗飙升近33%，新药迎重大进展；Ionis制药涨近35%
医药股彻底疯狂！美国联合医疗飙升近33%，新药迎重大进展；Ionis制药涨近35%，实验性药物临床数据乐观；MLYS大涨逾80%，高血压新药市场前景广阔>>
09-03 15:53
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company, announced that it will report top-line data from its Phase 2 VIBRANT trial of verekitug, a monoclonal antibody targeting TSLP receptor, on September 2, 2025. The VIBRANT trial assessed verekitug's efficacy and safety in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), with the primary endpoint being the change in endoscopic nasal polyp score at Week 24. The co...
09-01 21:00
Two Harbors Investment to pay $375M to settle Pine River litigation
Two Harbors Investment (NYSE:TWO) agreed to pay $375M in cash to settle all litigation related to terminating its management agreement with PRCM Advisers LLC, Pine River Capital Management LP, and Pin...
08-21 04:40
Claros Mortgage Trust outlines $2B+ loan resolution trajectory while advancing REO strategies
Earnings Call Insights: Claros Mortgage Trust (CMTG) Q2 2025 Management View Richard Jay Mack, CEO, stated that while "the elevated rate environment remains a headwind for commercial real estate, we'r...
08-08 17:33
Upstream Bio, Inc. Reports Increased R&D Investments
Upstream Bio, Inc. ( ($UPB) ) has released its Q2 earnings. Here is a breakdown...
08-07 14:51
Upstream Bio, Inc. reports Q2 results
Upstream Bio, Inc. press release (NASDAQ:UPB): Q2 Revenue of $0.9M. Net loss was $40.0 million for the quarter ended June 30, 2025, compared to a net loss of $14.7 million for the same period in 2024....
08-06 19:48
Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress
Upstream Bio reported Q2 2025 financial results and highlighted recent business milestones. The company advanced Verekitug, a monoclonal antibody targeting TSLP receptor, in Phase 2 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Enrollment was completed in the severe asthma trial in June 2025, with top-line data expected in Q1 2026. The first patient was dosed in the ...
08-06 11:00
Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on ...
07-28 22:29
Upstream Bio Doses First COPD Patient in Phase 2 Trial for Anti-Inflammatory Drug Verekitug
Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the first patient has been dosed in
07-08 19:02
